Tumor-Specific Cancer Vaccine Adjuvant Formulation

SUMMARY

• Many cancer vaccines fail due to insufficient CD8+ T cell targeting.  To save patient lives, oncologists need tumor-specific vaccines that increase CD8+ T cell response.
• The inventors developed and validated an intra-tumoral vaccine adjuvant for muringe melanoma.  They used a p(ManTLR7) glyco-polymer to chemically link to tumor cell binding moieties (i.e., (f(ab)₂, fAb, scFv, etc.).  Their adjuvant conjugation Anti-p(Man-TLR7) augmented tissue localization and biodistribution.
• Anti-p(Man-TLR7) builds on earlier use of p(Man-TLR7) as a priming agent for strong CD8+ T cell responses to traditional model antigens and malaria vaccination models.
• The team's in vivo experiments with B16F10 tumor-bearing mice demonstrated that Anti-p(ManTLR7) outperforms CpG, a TLR9 stimulating adjuvant, for tumor size reduction and survival rate.

FIGURE

ADVANTAGES

ADVANTAGES

• The tumor serves as a source of antigen to which immune responses are generated.
• Based on CpG's track record, this approach is scalable from melanoma to breast cancer, colon cancer, glioblastoma, lymphoma, sarcoma, and ovarian cancer.
• Anti-TRP1-pManTLR7 exhibits low potential for off-target effects and overall tolerability.

APPLICATIONS

• Monotherapy
• Immune checkpoint inhibitors

Jun 2, 2021

Licensing,Co-development

In vivo murine melanoma experiments|Ex vivo experiments (single-cell suspensions from spleen or lymph nodes under flow cytometry analysis)

Patent Pending

Jeffrey Hubbell

• Iteration of Hubbell Lab Patent WO2017058996A1